U.S. License Holder:
Ridgeback Biotherapeutics
Date of License:
December-21-2020
Last Update:
Nov-15-2023
FDA-Approved Indications
EBANGA (ansuvimab-zykl) is a Zaire ebolavirus glycoprotein (EBOV GP)-directed human monoclonal antibody indicated for the treatment of infection caused by Zaire ebolavirus in adult and pediatric patients, including neonates born to a mother who is RT-PCR positive for Zaire ebolavirus infection.